Mutations in UGT genes in the tumor that reduce the glucuronidation of anticancer drugs can increase intratumoral drug concentrations, thus potentially enhancing therapy efficacy and inhibiting tumor growth. The gene discussed is SLC35A2; the disease is neoplasm.